University Hospital Of Clermont-Ferrand

At University Hospital Of Clermont-Ferrand, clinical research in hepatogastroenterologie focuses on Digestive System Diseases and Neoplasms, with particular attention to unresectable hepatocellular carcinoma. These studies are designed to evaluate whether new treatment strategies can improve outcomes for patients with advanced liver cancer.

• Testing a new therapy combined with standard treatment for unresectable hepatocellular carcinoma
• Assessing the effectiveness of treatment approaches in liver cancer
• Comparing whether adding novel care can improve first-line results for patients with advanced disease

This research reflects a strong clinical interest in improving treatment options for difficult-to-treat digestive system cancers through more effective and patient-focused care.

The site is also involved in studies within Genetic Phenomena, especially rare conditions such as Megalencephaly-CApillary malformation Polymicrogyria syndrome. University Hospital Of Clermont-Ferrand contributes to research aimed at understanding how targeted therapies may support patients with complex neurodevelopmental and genetic disorders.

• Evaluating a targeted treatment for MCAP syndrome
• Studying whether therapy can improve adaptive behavior over time
• Advancing care for rare genetic and developmental conditions

These trials are intended to help clarify the potential of precision medicine in a rare disease setting where treatment options remain limited.

Research at this hospital also includes Neoplasms involving Acute Myeloid Leukemia, with studies focused on improving remission rates and treatment effectiveness. The goal is to determine whether newer approaches can lead to deeper and more durable responses in patients with this aggressive blood cancer.

• Comparing treatment strategies for newly diagnosed AML
• Measuring whether patients achieve deep remission after induction therapy
• Exploring better outcomes in genomically defined acute leukemia

This work supports ongoing efforts to refine hematologic cancer care by identifying approaches that may improve remission quality and overall treatment benefit.